Siemens AG announced to acquisition of Varian Medical Systems, Inc. to create a highly integrated portfolio of imaging, laboratory diagnostics, and artificial intelligence for the treatment of cancer, and establish a strong and trusted partner capable of supporting customers and patients across the entire cancer care. Furthermore, the acquisition will enable the company to address the growing need for personalized, data-driven diagnosis and precision cancer care and support oncology clinicians and patients in achieving better outcomes.
Varian Medical Systems, Inc. announced that it has obtained clearance from the FDA for the use of the first linear accelerators TrueBeam and Edge systems that are intended to accurately target tumors and other diseases using radiation. Furthermore, TrueBeam and Edge systems will be used to treat medically refractory essential tremors with stereotactic radiosurgery to improve the lives of many patients who might otherwise be forced to live with untreatable essential tremors.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5331
Published Date: Oct 19, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Rising cases of cancer across the globe and growing technological advancements are the major factors driving the growth of the market.
The market size of Stereotactic Surgery Devices is anticipated to attain a CAGR of 5.7% over the forecast period, i.e., 2024-2036.
The major players in the market are Hitachi Medical Systems, Huiheng Group, Siemens AG, Elekta AB, Varian Medical Systems, IBA, Accuray Incorporated, GE Healthcare, and others.
The breast segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.